DM us for participating in the prospective DO-IT registry and RCT

Excited to share our work on the safety of thrombolytics in patients on DOACs. Largest sample size in the literature. Great effort by my friend and partner Malik Ghannam If interested, please join DO-IT Trial Shadi Yaghi ahajournals.org/doi/10.1161/JA…

Espen Saxhaug Kristoffersen SPAVC Diana Aguiar de Sousa DO-IT Trial Thomas Meinel Great international effort to determine safety and efficacy of IV thrombolysis in patients on DOAC therapy. Grateful to have Espen Saxhaug Kristoffersen as part of this #teameffort DO-IT Trial Thomas Meinel Stroke Research Center Bern Teddy Wu Jan Purrucker

Thanks for highlighting the importance ti get additional data on IVT in patients on DOACS. We will just DO-IT Trial !@janpurrucker Thomas Meinel Teddy Wu Espen Saxhaug Kristoffersen Ashkan Shoamanesh Aristeidis Katsanos Luciana Catanese, MD Guri Hagberg Stroke Research Center Bern European Stroke Master Urs Martin Fischer

join -> DO-IT Trial

• 81 yo female • Aphasia, slight HP R, NIHSS 10 • LSW 2h ago • on Rivaroxaban, plasma level 334ng/ml • no LVO

The main question this excellent study raises is whether we should give IVT to patients on DOACs. Despite very high dose of thrombin inhibition by Argatroban and severe baseline imbalances favouring the other groups, there was no significant increase in sICH. ➡️Join DO-IT Trial

Definitely equipoise to randomize in the starting #RCT DO-IT Trial Reach out if interested David Seiffge Thomas Meinel Luciana Catanese, MD Urs Martin Fischer clinicaltrials.gov/study/NCT06571…

Preparing for my talk about #breakthroughstrokes at the Norwegian Stroke Meeting in Bergen tomorrow with my friend Espen Saxhaug Kristoffersen. Deep breath of beautiful Norwegian nature! Looking forward to discuss ELAPSE and DO-IT Trial Guri Hagberg Thomas Meinel Stroke Research Center Bern Else C. Sandset

The DO-IT Trial team celebrating at #WSC2024 on the heels of David Seiffge’s successful debate and Thomas Meinel’s successful Swiss National Sciences Foundation funding application! We’re looking forward to launching the trial imminently!! Stroke Research Center Bern PHRI.ca Population Health Research Institute 🇨🇦 #stroke #MedEd

Nearly half of all AF-related strokes are #breakthroughstrokes despite adequate anticoagulation therapy. Low rate of thrombolysis. Better secondary prevention treatments and efficacy data for IVT in DOAC patients needed to change guidelines ELAPSE DO-IT Trial Stroke Research Center Bern

DO-IT Trial McMaster Stroke Program Stroke Research Center Bern

Exciting News! Many thanks to our funding partners Schweizerischer Nationalfonds (SNF) and Helmut Horten Stiftung for funding our clinical trial #DOIT 🙏 Site openings all across 🇨🇭 are following. Stay tuned for updates as we prepare to launch 🇪🇺🌍 in 2025!

🚀BREAKING news! The first trial site for the DO-IT Trial has officially opened in Bern! 🎉🙌 A big thank you to everyone involved for their support and hard work. Stay tuned for more updates on site openings across Swtizerland! 🌍 #DOITTrial

🚨 Exciting news! 🚨 The first patient has been randomised into the DO-IT Trial! 🎉 A big congratulations to the trial team in Bern on this amazing achievement! This marks a major milestone! A huge thank you to everyone for making this possible! Stay tuned for more updates.

🚀BREAKING news! The second trial site for the DO-IT Trial has officially opened in St.Gallen! 🎉😁 We would like to welcome the trial team in St. Gallen to the DO-IT community, we are thrilled to have you on board. Stay tuned for the upcoming site opening in Basel…⏲️

🚨 University Hospital Basel is now an active site for the DO-IT Trial ! 🧠 We're one step closer to advancing stroke care for people suffering ischemic stroke despite #DOAC treatment. Learn more 👉 doit-trial.ch #DOIT Stroke Research Center Bern